Cartilage tissue engineering is a rapidly evolving intervention that aims to treat cartilage damage and has the potential to modulate the progression of osteoarthritis (OA).^[@bibr35-2325967114550781]^ Autologous chondrocyte implantation (ACI) is currently considered an effective treatment method for larger (≥2 cm^2^) lesions. In this 2-stage technique, first described by Brittberg et al,^[@bibr6-2325967114550781]^ autologous chondrocytes are harvested from a low load--bearing area of the knee, expanded in vitro, and reinserted into the defect. Cartilage-like regeneration and successful clinical outcomes of up to 20 years have been reported for this treatment.^[@bibr42-2325967114550781],[@bibr46-2325967114550781]^ Prognostic clinical factors that have been suggested to influence outcomes are patient age, defect characteristics, sports-related activity, time since symptom onset, and previous surgeries to the index knee.^[@bibr4-2325967114550781],[@bibr8-2325967114550781],[@bibr9-2325967114550781],[@bibr30-2325967114550781],[@bibr36-2325967114550781],[@bibr53-2325967114550781]^ In general, up to 20% of ACI treatments fail.^[@bibr20-2325967114550781],[@bibr27-2325967114550781]^ Factors that have been associated with these failures include previous surgeries to the index knee and female sex.^[@bibr27-2325967114550781]^ In recent years, molecular biomarkers have received more attention as they have the potential to provide an objective measure of a response to a therapeutic intervention.^[@bibr32-2325967114550781]^ Collagen type II staining in biopsy specimens from patients with good clinical outcome suggests chondrogenicity of the graft to be an important prognostic factor.^[@bibr41-2325967114550781]^ In addition, markers found in monolayer cultures such as fibroblast growth factor receptor 3 (FGFR3), bone morphogenic protein 2 (BMP2), collagen type II α1 (COL2A1), and aggrecan (ACAN) have been associated with cartilage formation in vivo while activin receptor--like kinase receptor 1 (ACVRL1) marked the loss of in vivo cartilage-forming potential.^[@bibr12-2325967114550781]^ The loss of chondrocyte differentiated characteristics in vitro has also been linked to a reduced sox-9 transcription factor.^[@bibr19-2325967114550781],[@bibr29-2325967114550781]^ In contrast, expression of the cytokine transforming growth factor (TGF)--β2 and several surface molecules such as chondroitin sulfate proteoglycan 4, syndecan 2, and CD44 have indicated high chondrogenic capacity.^[@bibr1-2325967114550781],[@bibr16-2325967114550781]^ However, evidence to support the relationship between the presence of biomarkers during the in vitro culture before the implantation and clinical outcome is lacking. Therefore, it is unclear whether these markers could be used as prognostic and quality measures in clinical practice when assessing the potency of the cells before they are modified (ie, redifferentiated) and used in cellular-based treatments. This is highly relevant for the treating surgeon and scientists as currently, potency assessment of the cells used in cell therapy is a requirement in the European Medicines Agency's regulation on advanced therapies (regulation \[EC\] 1394/2007) and also in the United States, where autologous cell therapies are considered drugs (Food Drug and Cosmetic Act, in 21 CFR 1270.1(c), 2006).

The purposes of this study were to identify new biomarkers to predict clinical outcomes and to evaluate if previously reported markers are predictive of clinical outcome.

Materials and Methods {#section1-2325967114550781}
=====================

The expression of a predefined set of markers, including COL2A1, BMP2, FGFR3, ACAN, CD44, and ACVRL1 in the chondrocytes was used as a predictive measure. These markers were selected based on the literature, as their value in determining cartilage-forming potential has been reported previously.^[@bibr11-2325967114550781][@bibr12-2325967114550781]--[@bibr13-2325967114550781],[@bibr16-2325967114550781],[@bibr29-2325967114550781],[@bibr41-2325967114550781],[@bibr47-2325967114550781]^ The list of genes identified to be important for chondrogenic capacity of human chondrocytes by Dehne et al^[@bibr10-2325967114550781]^ were also investigated in the success and the failure groups. Furthermore, an unsupervised, global analysis of gene transcription was also performed, and genes and pathways that deviated between the success and failure groups were identified. Software programs were used to conduct a multivariate analysis of the array results.

Patients {#section2-2325967114550781}
--------

Included patients received ACI using a Hyalograft C scaffold as treatment of a cartilage defect in the knee between 2006 and 2008. Indications for ACI included patients who had been operated on before using microfracture but without success and with defects larger than 3 cm^2^.

The patients were divided into 2 groups: graft success and graft failure. The inclusion criteria for both groups were age 18 to 45 years, a maximum of 1 previous treatment to the index knee, and a single lesion in 1 knee. A failure was defined as a patient requiring reintervention due to the patients having developed pain and disability and magnetic resonance imaging and/or arthroscopy showing a poor healing of the repair within 3 years after surgery without a traumatic or other apparent cause for failure. Exclusion criteria included axis deviation or another known cause for failure such as a direct trauma. If patients met the inclusion criteria, they were selected for the success group if they achieved a highly statistically significant improvement (*P* \< .01) in clinical outcome scores 3 years after ACI. The clinical outcome was measured with the Knee Injury and Osteoarthritis Outcome Score (KOOS), the Lysholm knee rating scale, the Tegner activity scale, and a subjective evaluation of clinical improvement (SECI). The KOOS is a 5-subscale questionnaire designed for follow-up of knee injury and osteoarthritis that has been validated for follow-up of cartilage lesions.^[@bibr3-2325967114550781],[@bibr45-2325967114550781]^ The Lysholm scale is an 8-item questionnaire originally designed for anterior cruciate ligament reconstruction and modified to assess articular cartilage damage.^[@bibr48-2325967114550781]^ The Tegner activity scale measures the activity level in a 10-item scale.^[@bibr50-2325967114550781]^ All patients were treated in the same cartilage repair center by the same surgeon and consented to participate. Analysis of cartilage biopsies as well as clinical follow-up of the patients was approved by the institutional review board and performed during the same study period. For all patients, the Hyalograft C scaffold was seeded with 8 to 16 × 10^6^ cells.

Chondrocyte Culture {#section3-2325967114550781}
-------------------

Cartilage biopsies were taken, and chondrocytes for the ACI procedure were isolated as described.^[@bibr6-2325967114550781]^ Surplus chondrocytes were taken from the same expanded pool of autologous chondrocytes that were implanted in the patients, at the time point when the scaffold was seeded, and immediately frozen in liquid nitrogen. The surplus chondrocytes thus represented the transplanted chondrocytes before initiation of cellular modification (ie, chondrogenic redifferentiation). All patient-specific chondrocytes were thawed, at the same time point, and cultured for 1 cell doubling as previously described,^[@bibr6-2325967114550781]^ with the exception of a pooled human serum batch instead of autologous serum.

Total RNA Isolation {#section4-2325967114550781}
-------------------

Total RNA from the cultured chondrocytes was extracted with an Allprep DNA/RNA/Protein Mini Kit (Qiagen) according to the manufacturer's protocol for monolayer-cultured cells. RNA concentration was measured on a NanoDrop (Thermo Scientific), and the quality was verified using an Agilent Bioanalyzer (Agilent Technologies).

Microarray Analysis {#section5-2325967114550781}
-------------------

Total RNA from the failure and success chondrocytes was analyzed using global microarrays. To measure the mRNA expression, fragmented cDNA was hybridized at 45°C for 16 hours to whole transcript Gene ST 1.0 arrays (Affymetrix). The microarrays were scanned on a GeneChip Scanner 3000 7G (Affymetrix), and expression signals were extracted and normalized using the Expression Console (Affymetrix) applying the robust multichip average (RMA) normalization method.

Real-Time Quantitative Polymerase Chain Reaction {#section6-2325967114550781}
------------------------------------------------

Microarray results were verified by quantitative polymerase chain reaction (qPCR). Total RNA from corresponding samples were reverse transcribed in equal amounts with the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) on a 2720 Thermal Cycler (Applied Biosystems). Samples were analyzed in duplicates with equal amounts of cDNA and the TaqMan Universal master mixture with 1× assay-on-demand mixes of primers using the 7900HT Real-Time PCR system (Applied Biosystems). The genes analyzed with qPCR were selected from the predefined marker set and from genes annotated with enriched biological process terms in the gene ontology (GO) analysis (assay number in parentheses): COL2A1 (Hs00156568_m1), BMP2 (Hs00154192_m1), FGFR3 (Hs00179829_m1), ALK1 (Hs00163543_m1), ACAN (Hs00153936_m1), CD44 (Hs01075862_m1), PTPRD (Hs00369913_m1), PTPRF (Hs00892965_m1), ST6GAL2 (Hs00383641_m1), GCLC (Hs00155249_m1), PRLR (Hs01061477_m1), GRIK2 (Hs00222637_m1), LYST (Hs00915897_m1), AGT (Hs01586213_m1), FAIM2 (Hs00392342_m1), PHLDA1 (Hs00378285_g1).

Cyclophilin A (Hs99999904_m1) was used as a reference gene, and the relative quantification of target genes was performed according to the standard curve method calculated by the ΔΔCq method. Unpaired Student *t* tests were used to compare both groups in the qPCR validation of the microarray.

Data and Statistical Analysis {#section7-2325967114550781}
-----------------------------

### Patient Data {#section8-2325967114550781}

For the difference between patient demographics and postoperative and preoperative outcome scores, an unpaired and a paired *t* test were used, respectively.

### Clustering {#section9-2325967114550781}

To explore potential global differences between the 2 groups, a hierarchical clustering was performed using Pearson correlation and average linkage. Different filtering thresholds of background expression were evaluated.

### Identification of Differentially Expressed Genes {#section10-2325967114550781}

To identify genes that were differentially expressed between the success and failure groups, a Student *t* test was performed, and mean fold change values between the 2 groups were calculated for all genes. Genes with *P* values \<.05 and with a fold change \>20% were defined as differentially expressed genes (DEG).

### Gene Set Enrichment Analysis {#section11-2325967114550781}

To detect pathways that differ between the 2 groups, a gene set enrichment analysis (GSEA) was performed using the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways as gene sets. For details, see <http://www.broadinstitute.org/gsea/index.jsp>.

### Gene Ontology Analysis {#section12-2325967114550781}

To investigate the functional properties of the induced and repressed genes in the success group, a GO enrichment analysis was performed using the database for annotation, visualization, and integrated discovery (DAVID) bioinformatics resource.^[@bibr24-2325967114550781],[@bibr25-2325967114550781]^ The induced and repressed genes in the success group were used as an entry list, respectively, and all genes represented on the arrays were used as the reference list. Significantly overrepresented GO annotations for biological process were identified.

### Multivariate Analysis {#section13-2325967114550781}

The multivariate analysis was performed using SIMCA-P 12+ software (Umetrics AB). The centered and normalized raw data from the array including all 10 patients were analyzed with a principal component analysis (PCA) and a discriminant analysis using orthogonal partial least square analysis (OPLS-DA). The 5% of the variables that participated the most to the OPLS-DA were used to perform PCA models for the 5 success patients and the 5 failure patients, respectively. The predictions for those models are visualized in a Coomans plot.

Subsequently, an OPLS-DA was performed with 3 randomly selected success and failure patients. PCA models were performed with the 5% of the variables that participated the most to the separation between the groups in this second OPLS-DA. Thereafter, the 2 failure and 2 success patients that were not used to produce the prediction models were fitted into the models previously created out of the 3 success and 3 failure patients, and the predictions were visualized with a second Coomans plot.

Results {#section14-2325967114550781}
=======

Patient Data {#section15-2325967114550781}
------------

A total of 5 patients were included in the success group and 5 patients in the failure group. [Table 1](#table1-2325967114550781){ref-type="table"} provides the patient characteristics for both groups. Six patients underwent a previous procedure to the index lesion with a mean time to ACI of 15 months (range, 12-33 months). No statistical difference in patient demographics was found (*P* \> .05). For the success group, the clinical improvement was significant in all outcome scores, with a mean improvement in Lysholm score of 16 points (range, 10-27 points; mean preoperative score, 61.80 ± 15.22; mean postoperative score, 77.60 ± 11.46; *P* = .009). For the overall KOOS score, the mean improvement was 31 points (range, 18-43 points; mean preoperative score, 50.35 ± 20.63; mean postoperative score, 81.67 ± 10.50; *P* = .002). All patients in the success group reported complete improvement on the SECI. The Tegner activity score showed increased activity postoperation for the success group ([Table 2](#table2-2325967114550781){ref-type="table"}). However, all patients in the failed group required a reintervention because of graft failure (mean time to failure, 11.2 months; range, 8-19 months). The Tegner score for the failure group was unchanged after the first operation (data not shown) but increased after reoperation ([Table 2](#table2-2325967114550781){ref-type="table"}).

###### 

Patient Characteristics of the Graft Success and Graft Failure Groups*^a^*

![](10.1177_2325967114550781-table1)

                  Age, y   Sex      BMI, kg/m^2^   Defect Size, cm^2^   Defect Location   Injury      Previous Surgeries   Treatment Delay, mo
  --------------- -------- -------- -------------- -------------------- ----------------- ----------- -------------------- ---------------------
  Success group                                                                                                            
   1              29       Male     20.6           2.7                  Trochlea          Chronic     MF                   111
   2              31       Female   21.5           7.5                  Patella           Chronic     ---                  180
   3              37       Female   32             6                    Patella           Traumatic   MF                   38
   4              33       Male     21.1           5                    MFC               Chronic     ---                  60
   5              41       Male     28.4           4.4                  MFC               Traumatic   MF                   36
   Average        34.2              24.72          5.12                                                                    85
   SEM            2.15              2.31           0.80                                                                    22.95
  Failure group                                                                                                            
   1              44       Male     26.8           2.25                 MFC               Traumatic   MF                   37
   2              34       Female   22.5           7.5                  Patella           Chronic     ACI                  100
   3              46       Female   27.1           1.5                  MFC               Chronic     ---                  12
   4              44       Male     35.1           4.5                  MFC               Traumatic   ---                  84
   5              38       Female   21.7           9                    Trochlea          Traumatic   MF                   24
   Average        41.2              26.64          4.95                                                                    51.4
   SEM            2.24              2.38           1.45                                                                    17.23

*^a^*ACI, autologous chondrocyte implantation; BMI, body mass index; MF, microfracture; MFC, medial femoral condyle; SEM, standard error of the mean.

###### 

Tegner Scores of the Graft Success and Graft Failure Groups*^a^*

![](10.1177_2325967114550781-table2)

  Success Group   Presymptom   Preoperation   Postoperation
  --------------- ------------ -------------- ------------------------
  1               8            3              5
  2               3            2              3
  3               5            2              3
  4               6            2              6
  5               7            2              5
  Mean            5.80         2.20           4.40
  SEM             0.86         0.20           0.60
  Failure Group   Presymptom   Preoperation   Post--Second Operation
  1               8            2              5
  2               6            2              4
  3               2            2              3
  4               5            2              4
  5               3            1              3
  Mean            4.80         1.80           3.80
  SEM             1.07         0.20           0.37

*^a^*SEM, standard error of the mean.

Comparative Gene Expression Analysis and Multivariate Analysis {#section16-2325967114550781}
--------------------------------------------------------------

The comparative microarray analysis did not reveal any global clustering between chondrocytes from the failure and success groups ([Figure 1](#fig1-2325967114550781){ref-type="fig"}). The normalized data from the microarrays was also subjected to multivariate analysis. PCA of the total genome also failed to show a clear expressional disparity that can separate the success and failure groups ([Figure 2A](#fig2-2325967114550781){ref-type="fig"}). Discriminant analysis using orthogonal partial least square analysis using the knowledge of success and failure classes as a discriminating variable did separate the global gene expression into 2 clear groups, representing success and failure patients. Selecting 5% of the transcripts that participated most to the separation of the success and failure groups resulted in a set of 1443 transcripts, as indicated in the PLS-DA loading plot ([Figure 2B](#fig2-2325967114550781){ref-type="fig"}). Using those transcripts as variables in PCA models for the success and failure groups resulted in an acceptable classification ([Figure 2C](#fig2-2325967114550781){ref-type="fig"}). However, a prediction analysis where a PCA model is made out of 3 randomly selected patients from each group and the selected 5% of the transcripts that separate these 6 patients in an additional OPLS-DA failed to predict the group classification of the 4 excluded patients ([Figure 2D](#fig2-2325967114550781){ref-type="fig"}). Only 30% of the transcripts correlated between the OPLS-DA performed with all 10 patients and the OPLS-DA performed with 3 randomly selected patients from the success group and the failure group, respectively (data not shown). Additional data from the cell cultures (passage number and number of cell doublings) or the variables patient age, sex, and lesion size could not contribute to a separation of the 2 groups in the PCA. Neither the predefined set of gene markers nor the genes identified to be important for chondrogenic capacity by Dehne et al^[@bibr10-2325967114550781]^ contributed to any separation of the 2 groups (data not shown). A Student *t* test was performed to identify genes with a low grade of differential expression between the failure and success groups. The *t* test identified 541 transcripts to be differentially expressed between groups. A total of 346 transcripts were induced in the success group and 195 transcripts in the failure group. The list of 541 transcripts was filtered to remove genes with small fold changes (\<1.2). This approach resulted in 39 genes that were induced and 38 genes that were repressed in the success group ([Tables 3](#table3-2325967114550781){ref-type="table"} and [4](#table4-2325967114550781){ref-type="table"}). No intergroup differences were found for the predefined gene set FGFR3, BMP2, COL2A1, ACAN, CD44, and ACVRL1 and the gene list published by Dehne et al^[@bibr10-2325967114550781]^ ([Figure 3](#fig3-2325967114550781){ref-type="fig"}).

![Dendogram showing no global clustering between the groups.](10.1177_2325967114550781-fig1){#fig1-2325967114550781}

![Multivariate data analysis of the centered and normalized array data. (A) Score plot of principal component analysis (PCA) of the centered and normalized data from the arrays including all 10 patients. (B) Loading plot of discriminant analysis using orthogonal partial least square analysis (OPLS-DA) of the data from the array including all 10 patients. Dots indicate the set of transcripts that participate most to the separation of the groups; black dots, the set of 1443 transcripts; gray dots, the cloud of excluded transcripts. (C) Coomans plot showing the prediction PCA models for the 5 success patients and the 5 failure patients where the 5% of the variables that participated the most to the OPLS-DA were used to perform the PCA. Dotted line, 5% confidence limit of the model. (D) Coomans plot showing the prediction for all 10 patients. In this analysis, 3 randomly selected patients from the success and failure groups were included. The 5% of the variables that participated the most in this OPLS-DA were used as data in the PCA models. The excluded patients failed to fit their respective model. Dotted line, 5% confidence limit of the model.](10.1177_2325967114550781-fig2){#fig2-2325967114550781}

![Heatmap of (A) chondrogenic genes and (B) the predefined set of gene markers showing no clustering of the success and failure groups. *(Continued)*](10.1177_2325967114550781-fig3){#fig3-2325967114550781}

###### 

Induced Genes in the Success Group

![](10.1177_2325967114550781-table3)

  Gene Description (Gene Symbol)                                                                                  UniGene ID   Gene Accession   Fold Change
  --------------------------------------------------------------------------------------------------------------- ------------ ---------------- -------------
  Transmembrane receptor protein tyrosine phosphatase signaling pathway (GO:0007185)                                                            
   Protein tyrosine phosphatase, receptor type, D (PTPRD)                                                         Hs.446083    NM_002839        1.5
   Protein tyrosine phosphatase, receptor type, F (PTPRF)                                                         Hs.272062    NM_002840        1.2
  Other sorted after fold change                                                                                                                
   ST6 β-galactosamide α-2,6-sialyltranferase 2 (ST6GAL2)                                                         Hs.98265     NM_032528        2.0
   Nik related kinase (NRK)                                                                                       Hs.209527    NM_198465        1.9
   Amyloid beta (A4) precursor protein-binding, family B, member 1 interacting protein (APBB1IP)                  Hs.310421    NM_019043        1.8
   Tumor necrosis factor, alpha-induced protein 6 (TNFAIP6)                                                       Hs.437322    NM_007115        1.8
   FLJ45950 protein (FLJ45950)                                                                                    ---          AK127847         1.7
   Zinc finger protein 257 (ZNF257)                                                                               Hs.283900    NM_033468        1.7
   Zinc finger protein, multitype 2 (ZFPM2)                                                                       Hs.431009    NM_012082        1.6
   Melanoma cell adhesion molecule (MCAM)                                                                         Hs.599039    NM_006500        1.5
   Nucleoside phosphorylase (NP)                                                                                  Hs.75514     NM_000270        1.5
   Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1)                                                 Hs.518055    NM_015541        1.4
   Olfactory receptor, family 1, subfamily F, member 2 (OR1F2P)                                                   Hs.651203    NR_002169        1.4
   Dihydropyrimidinase-like 3 (DPYSL3)                                                                            Hs.519659    NM_001387        1.4
   Zinc finger protein 185 (LIM domain) (ZNF185)                                                                  Hs.16622     NM_007150        1.4
   Chromosome 20 open reading frame 69 (C20orf69)                                                                 ---          BC118988         1.4
   Protease, serine, 2 (trypsin 2) (PRSS2)                                                                        Hs.622865    NM_002770        1.4
   Polymerase (RNA) III (DNA directed) polypeptide G (32 kDa) (POLR3G)                                            Hs.282387    NM_006467        1.4
   Lysophosphatidylcholine acyltransferase 2 (LPCAT2)                                                             Hs.460857    NM_017839        1.4
   Cadherin 6, type 2, K-cadherin (fetal kidney) (CDH6)                                                           Hs.171054    NM_004932        1.3
   Olfactory receptor, family 4, subfamily M, member 2 (OR4M2)                                                    Hs.709063    NM_001004719     1.3
   Chromosome 20 open reading frame 69 (C20orf69)                                                                 ---          BC118988         1.3
   Transmembrane protein 171 (TMEM171)                                                                            Hs.162246    NM_173490        1.3
   Homeobox C5 (HOXC5)                                                                                            ---          NM_018953        1.3
   Arrestin, beta 1 (ARRB1)                                                                                       Hs.503284    NM_004041        1.3
   FXYD domain containing ion transport regulator 6 (FXYD6)                                                       Hs.714294    NM_022003        1.3
   Chromosome 20 open reading frame 69 (C20orf69)                                                                 ---          BC118988         1.3
   Rieske (Fe-S) domain containing (RFESD)                                                                        Hs.399758    NM_001131065     1.3
   Small nuclear ribonucleoprotein polypeptide N // small nucleolar RNA, C/D box 115-25  (SNRPN // SNORD115-25)   Hs.555970    NR_003342        1.3
   Enolase superfamily member 1 (ENOSF1)                                                                          Hs.369762    NM_017512        1.3
   Wingless-type MMTV integration site family, member 7B (WNT7B)                                                  Hs.512714    NM_058238        1.3
   Islet cell autoantigen 1, 69 kDa (ICA1)                                                                        Hs.487561    NM_004968        1.3
   RNA, U5E small nuclear (RNU5E)                                                                                 ---          NR_002754        1.3
   C-fos induced growth factor (vascular endothelial growth factor D) (FIGF)                                      Hs.11392     NM_004469        1.3
   Cleavage and polyadenylation specific factor 4-like (CPSF4L)                                                   Hs.534707    NM_001129885     1.2
   ELOVL family member 6, elongation of long chain fatty acids (FEN1/Elo2, SUR4/Elo3-like,  yeast) (ELOVL6)       Hs.412939    NM_024090        1.2
   Complement component 3a receptor 1 (C3AR1)                                                                     Hs.591148    NM_004054        1.2
   Phosphatase and actin regulator 1 (PHACTR1)                                                                    Hs.436996    NM_030948        1.2
   Plastin 1 (I isoform) (PLS1)                                                                                   Hs.203637    NM_002670        1.2

###### 

Repressed Genes in the Success Group

![](10.1177_2325967114550781-table4)

  Gene Description (Gene Symbol)                                               UniGene ID   Gene Accession    Fold Change
  ---------------------------------------------------------------------------- ------------ ----------------- -------------
  Regulation of apoptotic process (GO:0042981)                                                                
   Prolactin receptor (PRLR)                                                   Hs.368587    NM_000949         1.3
   Pleckstrin homology-like domain, family A, member 1 (PHLDA1)                Hs.602085    NM_007350         1.2
   Lysosomal trafficking regulator (LYST)                                      Hs.532411    NM_000081         1.3
   Fas apoptotic inhibitory molecule 2 (FAIM2)                                 Hs.567424    NM_012306         1.3
   Angiotensinogen (serpin peptidase inhibitor, clade A, member 8) (AGT)       Hs.19383     NM_000029         2.0
   Glutamate receptor, ionotropic, kainate 2 (GRIK2)                           Hs.98262     NM_175768         1.8
   Glutamate-cysteine ligase, catalytic subunit (GCLC)                         Hs.654465    NM_001498         1.3
  Extracellular structure organization GO:0043062                                                             
   Chondroitin sulfate *N*-acetylgalactosaminyltransferase 1 (CSGALNACT1)      Hs.655166    NM_018371         1.3
   Muscle, skeletal, receptor tyrosine kinase (MUSK)                           Hs.521653    NM_005592         1.3
   Relaxin/insulin-like family peptide receptor 1 (RXFP1)                      Hs.591686    NM_021634         1.6
   Angiotensinogen (serpin peptidase inhibitor, clade A, member 8) (AGT)       Hs.19383     NM_000029         2.0
  Other sorted after fold change                                                                              
   Apolipoprotein D (APOD)                                                     Hs.522555    NM_001647         1.8
   Collagen, type XV, alpha 1 (COL15A1)                                        Hs.409034    NM_001855         1.7
   Gastrin-releasing peptide receptor (GRPR)                                   Hs.567282    NM_005314         1.6
   Olfactory receptor, family 52, subfamily K, member 3 pseudogene (OR52K3P)   Hs.162035    AF143328          1.6
   Sushi domain containing 2 (SUSD2)                                           Hs.131819    NM_019601         1.6
   Cytidine deaminase (CDA)                                                    Hs.466910    NM_001785         1.5
   Insulin-like growth factor binding protein 2, 36 kDa (IGFBP2)               Hs.438102    NM_000597         1.5
   Absent in melanoma 1 (AIM1)                                                 Hs.643590    NM_001624         1.4
   Platelet factor 4 variant 1 (PF4V1)                                         Hs.72933     NM_002620         1.4
   Aldo-keto reductase family 1, member B10 (aldose reductase) (AKR1B10)       Hs.116724    NM_020299         1.4
   Complement factor H-related 3 (CFHR3)                                       Hs.709217    NM_021023         1.3
   SH3 and multiple ankyrin repeat domains 2 (SHANK2)                          Hs.268726    NM_012309         1.3
   Cytochrome P450, family 4, subfamily F, polypeptide 11 (CYP4F11)            Hs.187393    NM_021187         1.3
   THO complex 3 (THOC3)                                                       Hs.484227    NM_032361         1.3
   Leucine-rich repeats and IQ motif containing 3 (LRRIQ3)                     Hs.644625    NM_001105659      1.3
   Protein kinase, cGMP-dependent, type I (PRKG1)                              Hs.654556    NM_001098512      1.3
   Late cornified envelope 2D (LCE2D)                                          Hs.490225    NM_178430         1.3
   KIAA0825 protein (KIAA0825)                                                 Hs.425123    AK130941          1.3
   Ankyrin repeat domain 22 (ANKRD22)                                          Hs.217484    NM_144590         1.3
   Olfactory receptor, family 3, subfamily A, member 3 (OR3A3)                 Hs.532689    NM_012373         1.2
   Olfactory receptor, family 4, subfamily N, member 2 (OR4N2)                 Hs.512490    NM_001004723      1.2
   Cyclin Y-like 2 (CCNYL2)                                                    Hs.568048    ENST00000345581   1.2
   Submaxillary gland androgen regulated protein 3A (SMR3A)                    Hs.701334    NM_012390         1.2
   Anthrax toxin receptor-like (ANTXRL)                                        Hs.538515    NR_003601         1.2
   CDC28 protein kinase regulatory subunit 2 (CKS2)                            Hs.83758     NM_001827         1.2
   Similar to bovine IgA regulatory protein (LOC492311)                        Hs.696360    NM_001007189      1.2
   Family with sequence similarity 18, member B (FAM18B)                       Hs.87295     AF151906          1.2
   5-hydroxytryptamine (serotonin) receptor 3 family member D (HTR3D)          Hs.448004    NM_182537         1.2

Gene Ontology Analysis {#section17-2325967114550781}
----------------------

The GO biological process term GO:0007185 "transmembrane receptor protein tyrosine phosphatase signaling pathway" showed to be enriched among the induced genes in the success group. The 2 genes that contributed to this term enrichment were PTPRD and PTPRF. The repressed genes in the success group showed enrichment of several terms related to a reparative potential, for example, the GO biological process terms GO:0042981 "regulation of apoptotic process" (contributing genes: GCLC, PRLR, GRIK2, LYST, AGT, FAIM2, PHLDA1) and the term GO:0043062 "extracellular structure organization" (contributing genes: CSGALNACT1, MUSK, RXFP1, and AGT).

Gene Set Enrichment Analysis {#section18-2325967114550781}
----------------------------

Gene set enrichment analysis with KEGG gene sets demonstrated 15 enriched gene sets in the failure group and 0 enriched gene sets in the success group ([Table 5](#table5-2325967114550781){ref-type="table"}). Among the 15 enriched gene sets in the failure group, the cytokine cytokine-receptor interaction pathway showed enrichment of several cytokines (IL3, IL8, IL19, IL20, IL22 IFNA16, IFNA21, IFNA8, IFNB1, and IFNK) (see the [Appendix](#app1-2325967114550781){ref-type="app"}).

###### 

Enriched Gene Sets From the KEGG Database in the Failure Group*^a^*

![](10.1177_2325967114550781-table5)

  Pathway Name                                            Size,   FDR q-value
  ------------------------------------------------------- ------- -------------
  HSA00350_TYROSINE_METABOLISM                            53      0.011
  HSA00641_3\_CHLOROACRYLIC_ACID_DEGRADATION              15      0.018
  HSA00071_FATTY_ACID_METABOLISM                          43      0.027
  HSA00120_BILE_ACID_BIOSYNTHESIS                         37      0.030
  HSA00010_GLYCOLYSIS_AND_GLUCONEOGENESIS                 60      0.035
  HSA04060_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION         233     0.087
  HSA00980_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450   54      0.094
  HSA00624_1\_AND_2\_METHYLNAPHTHALENE_DEGRADATION        20      0.127
  HSA00561_GLYCEROLIPID_METABOLISM                        52      0.146
  HSA00531_GLYCOSAMINOGLYCAN_DEGRADATION                  16      0.213
  HSA00360_PHENYLALANINE_METABOLISM                       25      0.219
  HSA04080_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION        228     0.221
  HSA00591_LINOLEIC_ACID_METABOLISM                       29      0.232
  HSA00620_PYRUVATE_METABOLISM                            40      0.234
  HSA00380_TRYPTOPHAN_METABOLISM                          53      0.243

*^a^*FDR, false discovery rate; KEGG, Kyoto Encyclopedia of Genes and Genomes.

Real-Time Quantitative Polymerase Chain Reaction {#section19-2325967114550781}
------------------------------------------------

Validations of the microarray results using qPCR were performed for genes selected for their contribution to the gene ontology enrichment analysis by DAVID. The qPCR confirmed the induced genes PTPRD, PTPRF, and ST6GAL2 and the repressed genes GCLC, PRLR, GRIK2, LYST, AGT, FAIME2, and PHLDA1 in the success group. The qPCR results also confirmed expression patterns seen in the microarray analysis. The gene expression variance was low in the success group for the genes GCLC, GRIK2, LYST, and AGT. Similar to the microarray analysis, no significant intergroup difference in expression was found for the predefined marker set FGFR3, BMP2, COL2A1, ACAN, CD44, and ACVRL1 ([Figure 4](#fig4-2325967114550781){ref-type="fig"}).

![Quantitative polymerase chain reaction validation of the results from the microarray analysis. Each value is plotted, and the mean is marked with a line. *P* \< .05 was considered significant.](10.1177_2325967114550781-fig4){#fig4-2325967114550781}

Discussion {#section20-2325967114550781}
==========

The most important finding of the present study was that microarray analysis revealed no difference in gene expression between failed and successful ACI while subtle differences could be identified in expression of apoptosis-related genes, interleukin signaling, and β-catenin regulation. These results are important, as the increased availability and use of articular cartilage repair create a need for supportive tools when predicting clinical outcome. Although the expression of the genes FGFR3, BMP2, COL2A1, ACAN, CD44, and ACVRL1 has been proposed to be involved in chondrogenesis in a mouse model, the cellular mechanisms behind a successful ACI remain elusive.^[@bibr12-2325967114550781]^ This encouraged us to thoroughly investigate the transcriptome from chondrocytes used in a human in vivo environment. We searched for expression patterns that could help predict the clinical outcome of ACI as well as reveal cellular mechanisms behind a successful ACI repair tissue, although the cellular fate of the implanted chondrocytes cannot be determined in the present study.

Despite the differences in clinical outcomes of the included groups, the microarray analysis showed no global clustering, indicating no transcriptional differences between the successful and failed ACI treatments. A prediction analysis testing the separation found in the OPLS-DA between the success and failure groups failed to predict the group classification of the excluded patients, indicating that there is no strong separation between the 2 groups. Thus, the model-defining transcripts do not discriminate between the 2 groups on a global scale but only for the selected group. The model-defining transcripts in the 2 models have to be the same to assess true predicting transcripts. In addition, the results showed no intergroup expressional differences in the gene set proposed to predict chondrogenic capacity, further emphasizing that the chondrocytes are seemingly alike before surgery, with no possibility to assess their chondrogenic potency based on gene expression.

Dell'Accio et al^[@bibr12-2325967114550781]^ found the marker set that was included in this study to be of importance for cartilage forming capacity in vivo. Nonclinical data have supported the introduction of a gene marker profile that included several of these markers to determine in vivo cartilage-forming potential of characterized chondrocyte implantation (CCI).^[@bibr11-2325967114550781],[@bibr13-2325967114550781],[@bibr46-2325967114550781]^ In a randomized controlled trial comparing CCI and microfracture, Saris et al^[@bibr47-2325967114550781]^ found CCI patients with a high gene profile score to achieve greater improvement from baseline at 36 months compared with lower gene scores. However, this correlation was not corroborated in the recent 5-year follow-up report.^[@bibr53-2325967114550781]^ Furthermore, similar clinical outcomes were found for both microfracture and CCI at the latest follow-up, suggesting that the used gene profile score is predictive of cartilage regeneration but not clinical outcome.^[@bibr34-2325967114550781]^ In a study by Pestka et al^[@bibr40-2325967114550781]^ on 252 consecutive ACI patients, neither the expression of CD44, ACAN, or COL2A1 nor cell density or viability after proliferation seemed to correlate with the grade of joint degeneration, defect etiology, or patient sex. In a similar study, Niemeyer et al^[@bibr38-2325967114550781]^ investigated the influence of cell quality on clinical outcome after ACI based on expression of CD44, ACAN, and COL2A1. Postoperative International Knee Documentation Committee (IKDC) subjective knee scores were reported to be significantly influenced by COL2A1 expression (*P* \< .05) at 6, 12, and 24 months and CD44 expression at 24 months. Interestingly, neither ACAN nor the number of viable cells correlated with clinical outcome. The reports mentioned above, taken together with the present results, raise the question of whether expression of these biomarkers is predictive of cartilage formation capacity in vivo and/or clinical outcome. It could be that aiming at more comprehensive prediction models, possibly including other biomarkers in the biopsy, synovium, and/or serum, as well as patient characteristics may better reflect the complexity of cartilage repair.^[@bibr8-2325967114550781],[@bibr14-2325967114550781],[@bibr22-2325967114550781],[@bibr30-2325967114550781],[@bibr39-2325967114550781],[@bibr52-2325967114550781],[@bibr54-2325967114550781]^

Therefore, this study searched for a more subtle expressional difference between the 2 groups, as such small differences might be missed by the stringent statistical analyses used in the microarray technology. Fine-tuning of gene expression has been reported in several differentiation studies and could possibly be of importance for the clinical outcome of ACI.^[@bibr5-2325967114550781],[@bibr17-2325967114550781]^ Thirty-nine genes were found to be induced and 37 genes to be repressed in the success group. Among the induced genes in the success group, PTPRD and PTPRF were included in the enriched GO term transmembrane receptor protein tyrosine phosphatase signaling pathway involved in the regulation of a variety of cellular processes, such as focal adhesion, migration, cell growth, differentiation, mitosis, and apoptosis.^[@bibr15-2325967114550781],[@bibr31-2325967114550781],[@bibr55-2325967114550781]^ PTPRD and PTPRF are closely related to each other,^[@bibr44-2325967114550781]^ and PTPRF is suggested to be a negative regulator of β-catenin tyrosine phosphorylation, which preserves focal adhesion via prevention of β-catenin release from E-cadherin.^[@bibr37-2325967114550781]^ Thus, PTPRF prevents accumulation of free β-catenin in the cytoplasm and may subsequently have a negative effect on β-catenin--mediated signaling. Canonical Wnt signaling is such a β-catenin--mediated signaling pathway that has been shown to be associated with activation of chondrocyte maturational genes, matrix degradation, and osteoarthritis.^[@bibr7-2325967114550781],[@bibr57-2325967114550781],[@bibr59-2325967114550781]^ The elevated PTPRD expression in the success group may indicate that these patients were less affected by degeneration as PTPRD is upregulated in intact cartilage biopsies as compared with damaged osteoarthritic cartilage within the same knee.^[@bibr51-2325967114550781]^ Similarly, Wnt7b expression, which is present during mouse limb development in perichondrial cells flanking the prehypertrophic chondrocytes, was also induced in the success group.^[@bibr23-2325967114550781],[@bibr56-2325967114550781]^ The roles of the genes mentioned above are unknown in ACI and need further investigation.

The present results further indicate that there is an enrichment of apoptosis-related genes among the repressed genes in the success group, including GCLC, PRLR, GRIK2, LYST, AGT, FAIM2, and PHLDA1. In validating these genes using qPCR, LYST was found to be significantly (*P* = .002) repressed in the success group. LYST plays a role in vesicle fusions, for example, of lysosomes, and has previously been identified in articular cartilage.^[@bibr18-2325967114550781],[@bibr33-2325967114550781]^ Dysfunction of LYST could result in greater propensity toward lysosome membrane permeabilization and subsequent cell death and/or an impaired plasma membrane repair due to defective lysosomal exocytosis.^[@bibr26-2325967114550781],[@bibr49-2325967114550781]^ Although chondrocytes used for ACI have been reported to contain a low level of apoptotic cells, the functions of the reported apoptosis-associated genes in ACI are unknown and warrants further investigation.^[@bibr58-2325967114550781]^ Pietschmann et al^[@bibr43-2325967114550781]^ suggested that research aiming at apoptosis may provide new insights in the influence of cell quality on clinical outcome as they found a negative correlation between the number of morphologic abnormal cells and clinical outcome after ACI.

In the present study, GSEA analysis suggests that there is an activation of the cytokine system in the chondrocytes from the failure group. The cytokine system is known to be involved in the pathogenesis of osteoarthritis and has serious adverse effects on cartilage extracellular matrix.^[@bibr21-2325967114550781],[@bibr28-2325967114550781]^ This finding is in line with the recent study by Albrecht et al,^[@bibr2-2325967114550781]^ which showed that IL-1β expression in the transplanted chondrocytes negatively correlate with clinical outcome.

There are limitations of the present study that need to be addressed. Although the selections of failed ACIs were based on patients requiring a reintervention due to graft failure within 3 years after surgery without a traumatic or other apparent cause for failure, a heterogeneity within the failed group could exist because of unknown factors such as lack of graft integration, a disturbed joint hemostasis, lifestyle, and/or different compliance to rehabilitation. The differences in defect size between the 2 groups may have influenced the study results. However, we consider the included sizes to be clinically relevant for both groups, and there is, to our knowledge, not necessarily a correlation between clinical outcome and the differences in defect sizes in this study. In addition, the number of included patients may not give sufficient statistical power to separate the 2 groups on the basis of gene expression differences. The chondrocyte dedifferentiation state after monolayer culture was not fully assessed in the present study as the cells underwent the same amount of expansion culture and were therefore considered to be equally affected. Furthermore, known markers of dedifferentiation (eg, collagen type I and versican) were not among the regulated genes between the 2 groups. The fate of the implanted cells is an important question that may affect the clinical outcome; however, it is outside the scope of the present study and challenging to study in patients without clinical risks. Although, the relatively low expressional differences between the 2 groups might have little or no effect on the clinical outcome, we would emphasize the possibility that fine-tuning of gene expression may lead to new insights in the cellular behavior after ACI and the identification of potential biomarkers. This is exemplified by the aforementioned gene PTPRF that is subjected to such expressional fine-tuning where high ectopic expression leads to activation of caspase-driven apoptosis.^[@bibr55-2325967114550781]^ As discussed above, Müller et al^[@bibr37-2325967114550781]^ reported that even such low differences as twice the endogenous levels of PTPRF were enough to reduce the free pool of β-catenin, which could be supportive of the present results.

Conclusion {#section21-2325967114550781}
==========

This is the first study that evaluates the differences in gene expression of the chondrocytes before they are used in ACI to assess the chondrogenic potency of the inserted cells based on clinical success or failure. The study shows that gene expression analysis of the expanded chondrocytes prior to ACI is not a robust means of predicting clinical outcome after ACI, a result of importance when addressing legislation regulating the potency aspect of cell therapies. The results reveal subtle differences in gene expression in apoptosis, interleukin signaling, and β-catenin regulation between the 2 groups prior to ACI, which can strengthen the basis for future studies aiming to further uncover cellular mechanisms in cartilage regeneration and provide reliable biomarkers for quality control in articular cartilage repair.

One or more of the authors has declared the following potential conflict of interest or source of funding: This research was funded by The Swedish Research Council, grant No. 2012-2517; IngaBritt and Arne Lundberg Research Foundation; The Sahlgrenska University Hospital, Western Region, grant No. ALFGBG-137801; and the University of Gothenburg.

Genes Contributing to the Enriched Cytokine Cytokine-Receptor Interaction PathwayGene SymbolGene DescriptionUniGene IDCCL11Chemokine (C-C motif) ligand 11Hs.54460CCL20Chemokine (C-C motif) ligand 20Hs.75498CCL26Chemokine (C-C motif) ligand 26Hs.131342CCL3Chemokine (C-C motif) ligand 3Hs.514107CCL5Chemokine (C-C motif) ligand 5Hs.514821CCL7Chemokine (C-C motif) ligand 7Hs.251526CCL8Chemokine (C-C motif) ligand 8Hs.271387CCR4Chemokine (C-C motif) receptor 4Hs.184926CCR5Chemokine (C-C motif) receptor 5Hs.536735CCR5Chemokine (C-C motif) receptor 5Hs.536735CCR8Chemokine (C-C motif) receptor 8Hs.113222 // Hs.716265CD40LGCD40 ligandHs.592244CSF2Colony stimulating factor 2 (granulocyte-macrophage)Hs.1349CSF3RColony stimulating factor 3 receptor (granulocyte)Hs.524517CX3CR1Chemokine (C-X3-C motif) receptor 1Hs.78913CXCL1Chemokine (C-X-C motif) ligand 1Hs.789CXCL10Chemokine (C-X-C motif) ligand 10Hs.632586CXCL16Chemokine (C-X-C motif) ligand 16Hs.716600CXCL2Chemokine (C-X-C motif) ligand 2Hs.590921CXCL3Chemokine (C-X-C motif) ligand 3Hs.89690CXCL5Chemokine (C-X-C motif) ligand 5Hs.89714CXCL6Chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2)Hs.164021CXCR6Chemokine (C-X-C motif) receptor 6Hs.34526CXCR4Chemokine (C-X-C motif) receptor 4Hs.593413EDAEctodysplasin AHs.105407EGFEpidermal growth factor (beta-urogastrone)Hs.419815GH2Growth hormone 2Hs.406754GHRGrowth hormone receptorHs.125180 // Hs.684631IFNA16Interferon, alpha 16Hs.56303IFNA21Interferon, alpha 21Hs.113211IFNA8Interferon, alpha 8Hs.73890IFNB1Interferon, beta 1, fibroblastHs.93177IFNKInterferon, kappaHs.591083IL15RAInterleukin 15 receptor, alphaHs.524117IL18R1Interleukin 18 receptor 1Hs.469521IL18RAPInterleukin 18 receptor accessory proteinHs.158315IL19Interleukin 19Hs.661017IL20Interleukin 20Hs.272373IL21RInterleukin 21 receptorHs.210546IL22Interleukin 22Hs.287369IL23RInterleukin 23 receptorHs.677426IL2RGInterleukin 2 receptor, gamma (severe combined immunodeficiency)Hs.84IL3Interleukin 3 (colony-stimulating factor, multiple)Hs.694IL7RInterleukin 7 receptorHs.591742 // Hs.635723IL8Interleukin 8Hs.624 // Hs.443948IL9RInterleukin 9 receptorHs.406228IL9RInterleukin 9 receptorHs.406228LTALymphotoxin alpha (TNF superfamily, member 1)Hs.36LTALymphotoxin alpha (TNF superfamily, member 1)Hs.36LTALymphotoxin alpha (TNF superfamily, member 1)Hs.36PF4Platelet factor 4Hs.81564PF4V1Platelet factor 4 variant 1Hs.72933PRLProlactinHs.1905PRLRProlactin receptorHs.368587TGFBR1Transforming growth factor, beta receptor 1Hs.494622TNFRSF11BTumor necrosis factor receptor superfamily, member 11bHs.81791TNFSF10Tumor necrosis factor (ligand) superfamily, member 10Hs.478275TNFSF14Tumor necrosis factor (ligand) superfamily, member 14Hs.129708TNFSF15Tumor necrosis factor (ligand) superfamily, member 15Hs.241382TNFSF4Tumor necrosis factor (ligand) superfamily, member 4Hs.181097XCL1Chemokine (C motif) ligand 1Hs.546295XCR1Chemokine (C motif) receptor 1Hs.248116
